Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod for vulvar Paget's disease
NL-OMON42251Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- May 2015
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of imiquimod in Extramammary Paget disease of the vulva (EMPDV) and Vulvar Paget disease (VPD), sponsored by Radboud University Medical Center. Primary endpoint: Clinical response to topical imiquimod. Started May 2015; status: active, not recruiting.
02
Drugs
imiquimod
03
Conditions
Extramammary Paget disease of the vulva (EMPDV)Vulvar Paget disease (VPD)
Beyond the preview
Go deeper on NL-OMON42251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42251.